An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
This observational study will assess the median time of treatment duration and the safety of
 Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data
 will be collected for approximately 24 months.
Inclusion Criteria:

 -  Patients with metastatic breast cancer in first line treatment who have completed
 treatment with Avastin

 Exclusion Criteria:

 -  Patients not willing or unable to signed written consent form